Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma
June 9th 2020Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.
Read More
Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma
June 8th 2020Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.
Read More
Exploring New Treatment Options In HCC
June 8th 2020This Onclive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC. Join us Thursday, June 23, 2020 at 8 PM EST.
Read More
Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
June 4th 2020In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.
Read More
Chowdhary Covers Risk-Reducing Strategies and Recommendations During the COVID-19 Era
June 2nd 2020Mudit Chowdhary, MD, shares advice for family members living with patients with cancer, projects the long-term implications of the COVID-19 pandemic on clinical practice, provides insight on the effects of investigational treatments for patients with COVID-19, and details the protocols Rush University Medical Center has put into place to limit the spread of the virus.
Read More
Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology
May 28th 2020In our exclusive interview, Dr. Karlan shares the rewarding moments and challenges she has encountered in the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.
Read More
Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives
May 25th 2020Howard A. "Skip" Burris, III, MD, FASCO, FACP, and Stephanie L. Graff, MD, discuss how the COVID-19 pandemic has affected cancer care, the collaborative efforts made between Sarah Cannon Research Institute and HCA to increase access to investigational COVID-19 treatments, and the steps ASCO has taken to ensure its members’ professional education and well-being during this time.
Read More
McGregor Details GU Treatment Guidelines During COVID-19 Pandemic
May 18th 2020Bradley McGregor, MD, discusses the purpose of the guidelines, some of the main factors that influenced the recommendations in genitourinary cancers, and the impact of the pandemic on some of the most common treatment interventions such as immunotherapy, chemotherapy, and hormonal therapy, for patients with these malignancies.
Read More
Dr. Huh on SGO COVID-19 Task Force Efforts
May 15th 2020Warner K. Huh, MD, discusses some of the key challenges faced in the management of gynecologic cancers in light of the COVID-19 crisis, shares some of the resources provided by the SGO COVID-19 task force, and projects what is needed to quell the pandemic, which he refers to as version of the Great Depression.
Read More
FDA Approval Insights: Olaparib/Bevacizumab in HRD+ Advanced Ovarian Cancer
May 14th 2020In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in HRD-positive advanced ovarian cancer.
Read More
The Uromigos Unveil Updates and Insights on the Impact of COVID-19 on GU Cancers
May 4th 2020In an effort to share some of the evolving knowledge about COVID-19 and how it is impacting the healthcare system on a global scale, the Uromigos group discusses statistics, strategies, and new studies as they relate to COVID-19 and patients with genitourinary cancers.
Read More
Marvels in Medicine: Dr. Gabriel Hortobagyi on Challenging Historical Dogmas in Breast Cancer
April 30th 2020In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.
Read More
Dr. Daver on Stem Cell Transplant Considerations in Hematologic Malignancies in Light of COVID-19
April 29th 2020Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.
Read More